際際滷shows by User: mxo128 / http://www.slideshare.net/images/logo.gif 際際滷shows by User: mxo128 / Mon, 03 Jun 2013 00:16:33 GMT 際際滷Share feed for 際際滷shows by User: mxo128 Characterization of sialoadenitis after administration of continuous sialogogues during the day and night after 131I therapy. /slideshow/salivary/22361615 whcsalivarymay312013-130603001634-phpapp02
]]>
]]> Mon, 03 Jun 2013 00:16:33 GMT /slideshow/salivary/22361615 mxo128@slideshare.net(mxo128) Characterization of sialoadenitis after administration of continuous sialogogues during the day and night after 131I therapy. mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/whcsalivarymay312013-130603001634-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Characterization of sialoadenitis after administration of continuous sialogogues during the day and night after 131I therapy. from Michael
]]> 276 3 https://cdn.slidesharecdn.com/ss_thumbnails/whcsalivarymay312013-130603001634-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Guidelines for the indications for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. /slideshow/poster-guidelines/22361614 posterguidelines2012guan5-31-2013-130603001633-phpapp01
]]>
]]> Mon, 03 Jun 2013 00:16:33 GMT /slideshow/poster-guidelines/22361614 mxo128@slideshare.net(mxo128) Guidelines for the indications for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/posterguidelines2012guan5-31-2013-130603001633-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Guidelines for the indications for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. from Michael
]]> 287 4 https://cdn.slidesharecdn.com/ss_thumbnails/posterguidelines2012guan5-31-2013-130603001633-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Guidelines for the prescribed activity for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. /slideshow/poster-activity/22361611 posteractivity2012guanpptv25-31-2013-130603001632-phpapp01
]]>
]]> Mon, 03 Jun 2013 00:16:32 GMT /slideshow/poster-activity/22361611 mxo128@slideshare.net(mxo128) Guidelines for the prescribed activity for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/posteractivity2012guanpptv25-31-2013-130603001632-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Guidelines for the prescribed activity for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. from Michael
]]> 237 4 https://cdn.slidesharecdn.com/ss_thumbnails/posteractivity2012guanpptv25-31-2013-130603001632-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Whole body retention of I-131 at 24hr vs 48hr as a predictor of maximum tolerated activity. /mxo128/atkins-24-hr-wbr-vs-5 atkins24hrwbrvs5-130603001630-phpapp02
]]>
]]> Mon, 03 Jun 2013 00:16:30 GMT /mxo128/atkins-24-hr-wbr-vs-5 mxo128@slideshare.net(mxo128) Whole body retention of I-131 at 24hr vs 48hr as a predictor of maximum tolerated activity. mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/atkins24hrwbrvs5-130603001630-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Whole body retention of I-131 at 24hr vs 48hr as a predictor of maximum tolerated activity. from Michael
]]> 287 3 https://cdn.slidesharecdn.com/ss_thumbnails/atkins24hrwbrvs5-130603001630-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Alpharadin<sup>速</sup> (Xofigo<sup>速</sup>) in the treatment of skeletal metastasis secondary to metastatic prostate cancer: an educational exhibit. /slideshow/alpharadin-educational-exhibit-post-5-312013-v20/22361607 alpharadineducationalexhibitpost5-31-2013v20-130603001629-phpapp02
]]>
]]> Mon, 03 Jun 2013 00:16:29 GMT /slideshow/alpharadin-educational-exhibit-post-5-312013-v20/22361607 mxo128@slideshare.net(mxo128) Alpharadin<sup>速</sup> (Xofigo<sup>速</sup>) in the treatment of skeletal metastasis secondary to metastatic prostate cancer: an educational exhibit. mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/alpharadineducationalexhibitpost5-31-2013v20-130603001629-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
Alpharadin<sup></sup> (Xofigo<sup></sup>) in the treatment of skeletal metastasis secondary to metastatic prostate cancer: an educational exhibit. from Michael
]]> 959 4 https://cdn.slidesharecdn.com/ss_thumbnails/alpharadineducationalexhibitpost5-31-2013v20-130603001629-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The utility of blind 131I treatments for differentiated thyroid cancer: an educational exhibit. /slideshow/blindtreatmentmay5-17v32013/22361605 blindtreatmentmay5-17v3-2013-130603001628-phpapp02
]]>
]]> Mon, 03 Jun 2013 00:16:28 GMT /slideshow/blindtreatmentmay5-17v32013/22361605 mxo128@slideshare.net(mxo128) The utility of blind 131I treatments for differentiated thyroid cancer: an educational exhibit. mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/blindtreatmentmay5-17v3-2013-130603001628-phpapp02-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
The utility of blind 131I treatments for differentiated thyroid cancer: an educational exhibit. from Michael
]]> 158 3 https://cdn.slidesharecdn.com/ss_thumbnails/blindtreatmentmay5-17v3-2013-130603001628-phpapp02-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 NaF SNM 2013 Mid-Winter Meeting /slideshow/naf-snm-2012-midwinter-meeting/16021696 posternafpet1-16-2013-130116091101-phpapp01
]]>
]]> Wed, 16 Jan 2013 09:11:00 GMT /slideshow/naf-snm-2012-midwinter-meeting/16021696 mxo128@slideshare.net(mxo128) NaF SNM 2013 Mid-Winter Meeting mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/posternafpet1-16-2013-130116091101-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
NaF SNM 2013 Mid-Winter Meeting from Michael
]]> 280 4 https://cdn.slidesharecdn.com/ss_thumbnails/posternafpet1-16-2013-130116091101-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 ThyCa Up to 7 Days 2013 SNM Mid-Winter Meeting /slideshow/thyca-up-to-7-days-2013-snm-midwinter-meeting/16021507 7daysthycanovdraft1-16-2013-130116085933-phpapp01
]]>
]]> Wed, 16 Jan 2013 08:59:33 GMT /slideshow/thyca-up-to-7-days-2013-snm-midwinter-meeting/16021507 mxo128@slideshare.net(mxo128) ThyCa Up to 7 Days 2013 SNM Mid-Winter Meeting mxo128 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/7daysthycanovdraft1-16-2013-130116085933-phpapp01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
ThyCa Up to 7 Days 2013 SNM Mid-Winter Meeting from Michael
]]> 146 2 https://cdn.slidesharecdn.com/ss_thumbnails/7daysthycanovdraft1-16-2013-130116085933-phpapp01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://public.slidesharecdn.com/v2/images/profile-picture.png https://cdn.slidesharecdn.com/ss_thumbnails/whcsalivarymay312013-130603001634-phpapp02-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/salivary/22361615 Characterization of si... https://cdn.slidesharecdn.com/ss_thumbnails/posterguidelines2012guan5-31-2013-130603001633-phpapp01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/poster-guidelines/22361614 Guidelines for the ind... https://cdn.slidesharecdn.com/ss_thumbnails/posteractivity2012guanpptv25-31-2013-130603001632-phpapp01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/poster-activity/22361611 Guidelines for the pre...